POINT Biopharma and Bach Biosciences announce licensing and partnership for canSEEK™ pan-cancer targeting technology

POINT Biopharma announced that it has entered into a definitive agreement with Bach Biosciences, a company commercializing the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston. The agreement provides POINT the exclusive global rights to commercialize the groundbreaking can-SEEK™ tumor targeting technology.‍

With canSEEK™, POINT expands its theragnostic oncology pipeline to include PNT2004, a pan tumor treatment. By seeking out highly expressed markers found in many tumors but not found in healthy tissue, canSEEK™ is a promising technology for use in next month generation radiopharmaceuticals, as it may allow for the precision treatment of a variety of solid tumor cancers.

Dr. McCann, CEO of POINT “An indication agnostic radioligand holds tremendous promise and we see this asset as a pipeline in a product, targeting multiple tumors, and making a difference for many patients, This product has unmatched tumor specificity and on target retention that we have not seen in other products and competitive molecules, giving us great hope as we bring this transformative product to patients in clinical trials.”

Professor Bachovchin will continue to develop the drug in partnership with POINT.  Beyond PNT2004, POINT has a strong pipeline of exciting radioligand treatments for several oncolo-gy indications.

Related Posts

Subscribe Our Newsletter